News Releases

Date Title and Summary View
May 27, 2020
U.S. FDA Approves New Pediatric Formulation of SIRTURO (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020  — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO Ò (bedaquiline). SIRTURO ® is now indicated for use as part of combination
May 18, 2020
Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio
NEW BRUNSWICK, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Society of Clinical
May 18, 2020
May 18, 2020
May 13, 2020
May 13, 2020
May 13, 2020
May 08, 2020
May 01, 2020
Apr 30, 2020
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.